# Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

> **NCT01064518** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Lateral Canthal Lines
- Crow's Feet
- Facial Wrinkles

## Interventions

- **DRUG:** Botulinum Toxin Type A
- **DRUG:** Placebo (Dose B)

## Key facts

- **NCT ID:** NCT01064518
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064518, "Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01064518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*